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A B S T R A C T
Now COVID-19 is causing a severe public health emergency and the mortality is rapidly increasing all over the
world. In the current pandemic era, although there have been many efforts to diagnose a number of patients with
symptoms or close contacts, there is no definite guideline for the initial therapeutic approach for them and
therefore, many patients have been dying due to a hyperinflammatory immunological reaction labeled as “cy-
tokine storm”. Severe patients are hospitalized and the treatment is done, though they have not been established
yet. Currently, however, no treatment is provided for those who are isolated at home or shelter until they get
severe symptoms, which will increase the harms to the patients. In this review, we discuss some important points
dedicated to the management of patients with COVID-19, which should help reducing morbidity and mortality.
In this era, we suggest 7 recommendations to rescue the patients and to reduce the morbidity and mortality due
to COVID-19 based on the immunological point of view.
1. Introduction
Coronavirus Disease 2019 (COVID-19) is a severe public health
emergency worldwide caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) [1]. The number of confirmed cases and
the mortality rate are increasing worldwide and the World Health Or-
ganization (WHO) acknowledged COVID-19 as a pandemic on March
11, 2020 [2]. Currently, there have been many efforts to diagnose a
number of patients with symptoms or close contacts to prevent the
spread in the community. This may prevent some spreading of the
virus, but not perfectly. Moreover, many confirmed cases are occurring
through diagnosis, but there is no definite guideline for the initial
therapeutic approach for them and therefore, many patients have been
dying. If the COVID-19 symptoms are severe, the patients are hospita-
lized and the treatment is done, though they have not been established
yet. Currently, however, no treatment is provided for those who are
isolated at home or shelter. Among them, there will be also some cases
in whom severe lung injury or cytokine storm has progressed [3],
leading to sudden death. Case fatality rates in some countries, espe-
cially Italy and Spain, are high and effective therapeutic measures are
urgently needed [4]. In this review, we discuss some important points
dedicated to the management of patients with COVID-19, which should
help reducing morbidity and mortality.
2. How much do we know about the pathophysiology of COVID-
19-associated lung injury and death?
Patients with COVID-19 have higher leukocyte numbers, C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, and an
imbalance of pro−/and anti-inflammatory cytokines and chemokines
with increased levels of interleukin (IL)-1β, IL-1RA, IL-7, IL-8, IL-9, IL-
10, basic fibroblast growth factor (FGF)2, granulocyte-colony stimu-
lating factor (G-CSF), granulocyte-macrophage colony stimulating
factor (GM-CSF), interferon (IFN)-γ, IFN-γ induced protein (IP)-10,
monocyte chemoattractant protein (MCP)-1, macrophage inflammatory
protein (MIP)1-α, MIP1-β, platelet derived growth factor (PDGF)-B,
tumor necrosis factor (TNF)-α, and vascular endothelial growth factor
(VEGF)-A [5]. Higher expression levels of IL-2, IL-7, IL-10, G-CSF, IP-
10, MCP-1, MIP1-α, and TNF-α were found in individuals admitted to
the intensive care unit (ICU) [5]. These cytokines may indicate patients
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at risk to develop acute lung injury, followed by acute respiratory dis-
tress syndrome (ARDS) and eventually death. This circumstance is
called cytokine release syndrome (CRS) or “cytokine storm” [6].
The main pathogenesis of COVID-19 may be similar to that of other
viruses such as influenza or others. However, there have been few ef-
forts to make a potential hypothesis why COVID-19 could cause a
higher incidence of acute lung injury, ARDS, cytokine storm and death
than other viruses. We are going to make a simple hypothetical model
for the inflammatory processes and “cytokine storm” for COVID-19 to
understand the pathophysiology of COVID-19 and its associated lung
injury, ARDS and cytokine storm.
• First, COVID-19 (SARS-CoV-2) is first attached to the angiotensin
converting enzyme 2 (ACE2) receptors in the nasopharynx and re-
spiratory epithelium [7].
• Second, host immune responses are initiated after entry of COVID-
19 into the cells and the pro-inflammatory cytokines induced by
COVID-19 are formed by various kinds of immune cells such as T
cells, B-cells, and macrophages, and others [8,9].
• Third, the degree of increase in pro-inflammatory cytokines de-
termines the degree of COVID-19-induced lung injury. The more
increase in pro-inflammatory cytokines, the higher the injury to
lung tissue and the more severe the ARDS, which could be related to
higher mortality.
• Fourth, the degree of increase in pro-inflammatory cytokines in
COVID-19 is higher as induced by other viruses. Especially, this
effect is more pronounced in older age and comorbid conditions.
• Fifth, the reason why this effect is less pronounced in younger age
groups may be obscure, but it could be due to the immaturity of
immune system and the predominance of Th2 immunity than Th1 in
these groups.
• Sixth, the reason why this effect is more pronounced in older age
groups and those with comorbid conditions may be obscure, but it
could be due to pre-existing subclinical or subtle inflammations,
represented by increased high-sensitive CRP (hsCRP) in these
groups.
• Seventh, the exaggerated increase in pro-inflammatory cytokines in
COVID-19 could be due to hyperactivation of various kinds of im-
mune cells in response to N-protein of COVID-19, which is called
“cytokine storm”.
• Eighth, this increase in pro-inflammatory cytokines induced by
COVID-19 (“cytokine storm”) can cause acute lung injury, ARDS and
eventually multiorgan failure.
• Ninth, “cytokine storm” may start from the early course of disease to
later stage according to the degree of activation of host immune
response and it may be rapidly progressive at any time.
• Tenth, there may be clinico-pathologic non-correlations between
them [3]. The patient may be asymptomatic or have mild symptoms
despite severely progressed conditions, which will delay the ap-
propriate treatment at an early stage.
3. Understanding of the pathogenesis of COVID-19: more
immunological activation than other usual respiratory viruses
The pathogenesis of COVID-19 is summarized in Fig. 1. Regarding
our immunity, there are 3 states: (1) immunosuppressive state, (2)
normal immune state (this is also classified as lower normal, normal,
and upper normal), and (3) hyperimmune state. If there are 100 normal
persons, they are distributed from 0 to 100 on a scale according to the
degree of anti-viral immunity, which will be mostly represented by Th1
response. If the person is immunocompromised, he/she will have minus
points on the scale. The lower the minus number is located, the more
severe the immunosuppressive condition will be. If the number is
higher than 100, the person will get hyperactivated host immune re-
sponse and will have lung injury, ARDS and multiorgan failure.
If the person is infected with other usual respiratory viruses, such as
rhinovirus or influenza, he/she will have fever and sore throat caused
by host immune response. However, the degree of increase in in-
flammatory reaction will be 3–5. So, if the person who has the number
of immunity scale of 90 and infected by other viruses, the number on a
scale will increase to 93–95. However, the degree of increase in in-
flammatory reaction in patients with the current COVID-19 will be
10–15. Therefore, if the person who has the number of immunity scale
90 is infected by COVID-19, the number on a scale will increase to
100–105, which means that there will be a high probability that this
patient will progress to “cytokine storm” due to hyperactivated immune
response, which might lead to death.
Because younger age groups' immune system may be immature and
they may have the predominance of Th2 immunity than Th1 [10], they
might have the number of immunity scale 0–30. Therefore, even though
they are infected by COVID-19 and the number is increased by 10-15 by
COVID-19, their number will be located between 10 and 45. Therefore,
there is a lower possibility that they will be progress to severe “cytokine
storm”, which may explain less mortality in this group.
However, the person in an older age group will have multiple co-
morbidities by aging process such as atherosclerosis, hypertension,
diabetes mellitus, metabolic syndrome and chronic kidney disease and
they might have pre-existing subclinical or subtle inflammations, re-
presented by increased hsCRP in these groups [11]. Therefore, they
might have a number of immunity scale 85–95. Therefore, if they are
infected by COVID-19 and the number of 10–15 is increased by COVID-
19, their number will be located between 95 and 110. Therefore, there
is high possibility that they will progress to severe “cytokine storm”,
which may explain high mortality in this group. Surely, there will be
additional factors that influence the susceptibility and severity of
COVID-19, such as genetic variant of different polymorphisms or en-
vironmental factors as smoking.
In addition to this basic 10–15 increase in the degree of in-
flammatory reaction, if the patient progressed to “cytokine storm”, the
number will rapidly increase to 200–300. We are going to discuss the
use of steroids later, but the basic increase of 10–15 in various pro-
inflammatory cytokines induced by COVID-19 might be suppressed by
short-course low dose steroids in an early stage of disease, but steroids
may not be effective in a later stage of disease such as ARDS and
multiorgan failure to suppress “cytokine storm” because 200–300
cannot be suppressed even though high dose of steroids are used.
Recently, hydroxychloroquine has been shown to be effective in
COVID-19 [12], and this drug may reduce the increase in the degree of
inflammatory reaction. However, we do not know which agent may be
better in decreasing inflammatory reactions and how much the number
might be decreased by steroids or hydroxychloroquine.
In addition to these, the rate of bacterial complications will increase
in accordance with the progression with time after COVID-19. We think
if bacterial complication is combined with “cytokine storm”, there will
be more severe inflammatory reactions. Although this theory may not
be perfect, this may be helpful to understand the pathogenesis and
potential harms of COVID-19 and guide how patients should be treated.
4. Can we apply evidence-based medicine for the treatment of
COVID-19?
Evidence based medicine (EBM) is the conscientious, explicit, ju-
dicious and reasonable use of modern, best evidence in making deci-
sions about the care of individual patients [13]. EBM integrates clinical
experience and patient values with the best available research in-
formation [13]. Many clinicians are applying the treatment to the
current coronavirus (COVID-19) based on the previous experiences for
MERS or SARS. However, this is not exactly evidence-based, since
COVID-19 is different. To be evidence-based, a large-scale randomized
placebo-controlled trial for COVID-19 should urgently be conducted.
However, it is too difficult to find an appropriate drug for COVID-19 in
a pandemic state, because it will take a long time, although this effort
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should also be done concurrently.
In addition, even if the results of small RCTs are meaningful, those
are often reversed when a larger RCT is performed [14]. Moreover,
although the results of meta-analysis may be considered to be the best
evidence, this should be interpreted with caution, because the meta-
analysis results can be significant even though all the results of in-
dividual RCTs have no statistical significance [15]. Furthermore, it has
been claimed that most published research findings are false and not
useful [16,17] (though this should also be interpreted with caution) and
numerously published meta-analyses are also misleading [18]. In ad-
dition, guidelines suggested by experts can also have a mistake [19]. In
this context, we should find what is the best strategies to protect the
humans form the harms of COVID-19. Even though we apply several
therapeutic strategies investigated in SARS or MERS, it should be in-
terpreted with caution. If we cannot apply EBM immediately in this
COVID-19 pandemic, we should also make every effort to find wise
ways to solve the problems. In this situation, an experience-based ap-
proach may be also important in this pandemic era and many pub-
lications should urgently be published even though they are case re-
ports or case series.
5. The basic principle for the treatment of patients: “Do no harm”
COVID-19 is causing a severe public health emergency all over the
word and the mortality is rapidly increasing all over the world. We
would like to remind of the basic principle for the treatment of patients,
but we often forget this: “Do no harm” [20]. We should think of what
“harms” means and what "do no harms" would look like in this pan-
demic. We have thought and summarized the potential harms and the
things we are doing now regarding COVID-19 and it is summarized as
below and Table 1.
(1) Continuing smoking is a significant harm to respiratory epithe-
liums. If so, why don't we recommend cessation of smoking at this
time? Not doing so is causing a significant harm to the patients.
(2) “Cytokine storm” is considered to be a significant harm and an
important cause of death. If so, why don't we make every effort to
prevent this process at an early course of disease? Not doing so is
causing a significant harm to the patients.
(3) Currently, some asymptomatic patients or those with mild symp-
toms have severe radiologic findings and bacterial complications
which can lead to sudden death, but no radiologic examinations
and treatment are done for these patients until severe symptoms
develop. This may be considered to be a significant harm. If so, why
don't we make every effort to detect these patients and treat them at
an early course of disease? Not doing so is causing a significant
harm to the patients.
(4) Currently, COVID-19 infected patients are divided into two groups:
one is the person who is isolated at home, but no medications are
provided and the other is the person who developed severe symp-
toms with time and admitted to the hospital. Currently, many pa-
tients with COVID-19 are recommended to be at home until severe
symptoms develop, due to infectivity to others. We think there will
be a patient group with moderate symptoms in whom if early
treatment is done with steroids and antibiotics, they will not pro-
gress to severe conditions. To let them at home will be a significant
harm. If so, why don't we provide medications such as steroids or
antibiotics at the time of COVID-19 test and monitor the patient
even by phone, considering it is practically difficult for the patient
Fig. 1. The pathogenesis of COVID-19 infection and cytokine storm. ALI: acute lung injury; ARDS: acute respiratory distress syndrome; MOF: multiorgan failure; CKD:
chronic kidney disease.
Table 1
Points of current potential harms in the novel COVID-19 disease.
• Smoking cessation has not been recommended in this pandemic era, which may
be a significant harm.
• Although “Cytokine storm” is considered to be a significant harm and an important
cause of death, there have been few efforts to prevent this process at an early course
of disease.
• The person with COVID-19 who is isolated at home does not receive any
medications or treatment until severe symptoms such as dyspnea develops.
• Although some asymptomatic patients with COVID-19 or those with mild symptoms
have severe radiologic findings, no radiologic examinations are given to these
patients until severe symptoms develop.
• Although some mild patients with COVID-19 have bacterial complications at any
stage, no treatment is given until severe symptoms develop.
• Misinterpretation of the results from various studies including systematic review
without considering the biases will lead to a false guidance for the treatment of
COVID-19, which will be a significant harm
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to visit the clinic again? If so, policy should be changed in this
pandemic era as medications should be given to the patients more
liberally than in usual situations. Not doing so is causing a sig-
nificant harm to the patients and hesitating for the use of steroids
and antibiotics may be a harm to the patients with COVID-19.
(5) Doing something is better than nothing. Currently, there are no
established guidelines for COVID-19 and we rely on the previous
treatments for SARS, MERS or influenza or on expert opinions.
Recently, some investigators are discussing the beneficial effect of
hydroxychloroquine for COVID-19, but this is just based on in vitro
studies and not much experience. But why don't we have more in-
terests on the use of elderberry supplements which was shown to be
effective in cold and influenza by randomized, double-blind, pla-
cebo-controlled study and meta-analysis [21–23]? If some treat-
ments such as elderberry supplements or betadine mouth or nasal
spray are not causing significant harms, we think doing something
is better than nothing.
(6) Misinterpretation of the various studies including systematic review
without considering the biases will lead to a false guidance for the
treatment of COVID-19, which will be a significant harm [24]. The
role of experts who are doing evidence-based medicine or meta-
research is very important to reduce the harm to the patients in this
pandemic era. (See Table 2.)
In addition to these, there may be more current harms in this pan-
demic era and this should also be urgently discussed.
6. Defense for COVID-19 in the pandemic era: 7 recommendations
to rescue the patients from COVID-19 infection
Based on the pathogenesis of COVID-19 infection and the principles
mentioned above, we would like to suggest 7 recommendations for
COVID-19 which should urgently be considered in this pandemic era.
6.1. Smoking cessation
First, smoking cessation should be encouraged. This has always
been recommended for general population, but it has also been very
difficult for the people to do so. Because COVID-19 can predominantly
damage the respiratory epitheliums and lungs, this should at least be
recommended. Recently, it was also hypothesized that those individuals
who have been exposed to nicotine prior to their exposure to the virus
are “primed” to be at higher risk because nicotine can directly impact
the putative receptor for the virus (ACE2) and lead to deleterious sig-
naling in lung epithelial cells. [25] In addition, several cytokines in-
cluding IL-2, IL-6 and TNF-α which is induced by smoking might trigger
“cytokine storm” in COVID-19. We still do not know whether a short
duration of smoking cessation could reduce the susceptibility or se-
verity of COVID-19 or not, but if it is beneficial, doing something
(smoking cessation) is better than nothing.
6.2. Povidone‑iodine mouth or nasal spray
Second, povidone‑iodine (polyvinylpyrrolidone‑iodine, PVP-I, be-
tadine) mouth or nasal spray can be applied to kill the COVID-19
viruses and it will reduce the number of COVID-19 viruses which enter
into the cells. COVID-19 is initiated by the attachment of the virus to
the pharynx or respiratory epithelium and this causes sore throat.
Currently, however, we do not know about whether the number of virus
attached to the pharynx or respiratory epithelium will influence on the
severity of COVID-19. Easily speaking, when you inhaled 10 viruses and
when you inhaled 1000 viruses, will infection risk or the disease se-
verity be same or different? Currently, this cannot be proved easily.
However, considering the effectiveness of a mask that prevents re-
spiratory infections, less exposure is likely to prevent infection by an
indirect evidence. One previous meta-analysis showed that physical
measures are highly effective in preventing the spread of SARS: wearing
masks (odds ratio 0.32, 95% CI 0.25 to 0.40; number needed to treat
(NNT) = 6, 4.54 to 8.03) vs. wearing N95 masks (0.09, 0.03 to 0.30;
NNT = 3, 2.37 to 4.06) [26]. We can make a potential hypothesis: if 10
viruses were inhaled and attached to the throat, this may be cleared by
host immunity. However, if 1000 viruses were inhaled and attached to
the throat, it should go through a fight between the virus and host
immunity. If viruses are cleared by host immunity, the person can be
free from virus, but if the viruses win, they may replicate exponentially
within a relatively short time and will cause viremia in the blood. In
this situation, we still do not know whether the degree of viremia (viral
load) might be correlated to the degree of host hyperimmune response,
or whether reduction of viruses in the throat, for example, using be-
tadine mouth spray or gargles, could decrease the degree of viremia in
blood.
Currently, inhibiting angiotensin converting enzyme 2 (ACE2) and
blocking angiotensin receptor 2 (AR2) is considered to be the key target
for SARS-CoV-2 vaccination and COVID-19 therapy [27]. Due to this
finding, some authors recommend the use of angiotensin converting
enzyme inhibitors (ACEI) or angiotensin receptor 2 blockers (ARBs)
[28]. Currently, these findings and suggestions can't be transferred into
clinical practice easily. ACEI and ARBs are widely used in clinical daily
practice, no clinical studies have been made in the set of COVID-19
outbreak so far. Even basic science, due to the pathophysiological
mechanisms (e.g. effectiveness of blocking AR2) are limited [27]. Due
to a substantiated benefit-risk evaluation a therapy with ARBs or ACEI
cannot be recommended. In addition, we do not know about how many
ACE2 receptors could be downregulated or blocked by antibodies or
vaccines and how many entries of viruses could be inhibited by these if
they are developed. However, if blocking entry of virus is a potential
therapeutic target, we think that direct killing of the virus in the throat
by betadine mouth or nasal spray might be more efficacious than the
receptor downregulation.
Several studies showed severe acute respiratory syndrome cor-
onavirus (SARS-CoV) and Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) could be inactivated by PVP-I in vitro
[29,30]. One phase 1 study shows application of PVP-I nasal spray to
the nasal mucosa did not result in any demonstrable limitation of the
nasal function nor in detectable damage to the multilayer ciliated epi-
thelium of the nose [31]. Because anyone can buy betadine mouth or
nasal spray or gargles without a prescription as over-the-counter
medicines, if it does not cause any significant harm, there is no reason
not to use it and it can be applied if a person feels sore throat at an early
course of the disease. Although side effects of PVP-I use are rare, the
adverse effect of iodine and other precautions should also be re-
cognized. PVP-I can cause allergic reactions and should not be used in
patients suffering from thyroid diseases [32]. Even there exist no stu-
dies for PVP-I and SARS-CoV-2 either due to the benefit-risk evaluation,
PVP-I can be used in patients infected with SARS-CoV-2 with no or mild
Table 2
Summary points of 7 recommendations which should urgently considered in the
novel COVID-19 disease.
• Smoking cessation should be encouraged.• Povidone-iodine (polyvinylpyrrolidone-iodine, PVP-I, betadine) mouth or nasal
spray can be considered.
• The use of elderberry supplements can be considered at an early course of the
disease.
• The use of low dose oral steroids should be actively considered at an early course of
the disease.
• The use of oral antibiotics should be actively considered if the patient feels not
good.
• Hydroxychloroquine can be used as a secondary drug in patients with worsening
symptoms.
• Policy for the drug use should be changed like giving steroids and antibiotics to the
patients at the time of diagnostic test or by drive through system to reduce the
harms of patients.
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symptoms without allergies to PVP-I or thyroid diseases. Or if a person
is visiting more crowded places such as airport, it can also be applied
easily.
6.3. The use of elderberry supplements at an early course of disease
Third, the use of elderberry supplements should be considered at an
early course of the disease. Although it has not been tested in cor-
onavirus, elderberry supplements which was shown to be effective in
cold and influenza by randomized, double-blind, placebo-controlled
study and meta-analysis [21–23]. Currently, there was one Cleveland
clinic news reported by Emily Bamforth on the use of elderberry sup-
plements [33]. Although there have been several reports on the bene-
ficial effect of elderberry supplements on several viral infections
[21–23], there have been few hypotheses on the potential immunologic
mechanisms on the beneficial effect of elderberry supplements focusing
on COVID-19.
It is well known that angiotensin-converting enzyme 2 (ACE2) is a
receptor for SARS-CoV [34]. A recent study showed that SARS-CoV-2
(COVID-19) spike (S) glycoproteins also uses ACE2 to enter cells and
that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S
bind with similar affinities to human ACE2, correlating with the effi-
cient spread of SARS-CoV-2 among humans. [35]. Although less dis-
cussed than ACE2, it was shown that CD209L (L-SIGN), encoded by
CLEC4M, is also a receptor for SARS-CoV [36]. In this study, CD209L
was expressed in human lung in type II alveolar cells and endothelial
cells, both potential targets for SARS-CoV and the large S glycoprotein
of SARS-CoV might use both ACE2 and CD209L in virus infection and
pathogenesis [36]. In addition, Chan et al. demonstrated that in-
dividuals homozygous for CLEC4M tandem repeats are less susceptible
to SARS infection and L-SIGN is expressed in both non-SARS and SARS-
CoV-infected lung [37]. They also showed that compared with cells
heterozygous for L-SIGN, cells homozygous for L-SIGN show higher
binding capacity for SARS-CoV, higher proteasome-dependent viral
degradation and a lower capacity for trans infection, suggesting that
homozygosity for L-SIGN plays a protective role during SARS infection
[37]. In summary, the first encounter of the virus with the host might
be through binding to attachment receptors, such as these receptors,
which might play an important role of infection for a large number of
enveloped viruses by capturing, concentrating and transmitting in-
fectious virions [38]. Once a virus reaches its target cell, a cascade of
events generally starting with the interaction of viral envelope glyco-
proteins with specific entry receptors and co-receptors is necessary in
order to trigger the virus-cell membrane fusion [38].
Although not much studied in coronavirus, capture and transmis-
sion of HIV-1 by the C-type lectin L-SIGN was inhibited by carbohy-
drate-binding agents (CBAs) [39]. In this study, both mannose- and N-
acetylglucosamine (GlcNAc)-specific CBAs dose-dependently prevented
virus capture by L-SIGN-expressing 293 T-REx/L-SIGN cells [39]. Be-
cause coronavirus also uses L-SIGN as a receptor for entry, one study
suggested that influenza virus and coronavirus infections might also
qualify to be treated by CBAs [40].
Keyaerts et al. evaluated the effect of 33 plant lectins with different
specificities to coronavirus [41]. They showed that the plant lectins
possessed marked antiviral properties against both coronaviruses with
EC(50) values in the lower microgram/ml range (middle nanomolar
range), being non-toxic (CC(50)) at 50–100 microg/ml and the stron-
gest anti-coronavirus activity was found predominantly among the
mannose-binding lectins. In addition, a number of galactose-, N-acet-
ylgalactosamine-, glucose-, and N-acetylglucosamine-specific plant ag-
glutinines exhibited anti-coronaviral activity [41]. They also found that
there was a significant correlation (with an r-value of 0.70) between the
EC(50) values of the 10 mannose-specific plant lectins effective against
the two coronaviruses but, little correlation was seen between the ac-
tivity of other types of lectins [41]. Therefore, they reported that two
targets of possible antiviral intervention were identified in the
replication cycle of SARS-CoV; the first target is located early in the
replication cycle, most probably viral attachment, and the second target
is located at the end of the infectious virus cycle [41].
De Clercq summarized various compounds which have been re-
ported to exhibit in vitro activity against SARS-CoV, though they have
an ill-defined mode of action but selectivity indexes up to 100 (vali-
nomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyr-
rhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and
calpain inhibitors). Among them, plant lectins and chloroquine (which
is being discussed for the potential treatment of COVID-19) are in-
cluded [42].
This hypothesis has further been tested later in MERS-CoV epi-
demic, because coronaviruses are enveloped viruses, with the spike
proteins present on their surface responsible for virus entry into the
target cell [43]. Because MERS-CoV also cause a high mortality rate of
about 35%, no vaccine is available and therapeutic options for MERS-
CoV infections are limited to palliative and supportive care, a search for
specific antiviral treatments was urgently needed [43]. Millet et al.
thought that lectins are attractive anti-coronavirus candidates because
of the highly glycosylated nature of the spike protein and tested the
antiviral effect of griffithsin (GRFT), a lectin isolated from the red
marine alga Griffithsia sp. against MERS-CoV infection [43]. They de-
monstrated that griffithsin is a potent inhibitor of MERS-CoV infection
without significant cytotoxicity [43]. Griffithsin inhibited entry into
host cells of particles pseudotyped with the MERS-CoV spike protein,
suggesting that griffithsin inhibits spike protein function during entry at
the binding step [43].
The compounds found in elderberries are phenolic acids, flavonoids,
vitamins, lectins and aroma compounds, etc. [44]. A very similar lectin
called Sambucus nigra fruit specific agglutinin I (SNA-If) was identified
as a minor protein in ripe elderberry fruits [45]. Although elderberry
supplements have not been tested in the current COVID-19 pandemic,
lectin components might inhibit spike protein function during entry at
the binding step as mentioned above or have unknown other effects.
Currently, because anyone can buy elderberry supplements without
a prescription as over-the-counter medicines, if it does not cause any
significant harm, there is no reason not to use it and it can be applied at
an early course of the disease. Although there have been some reports
on the increase in some cytokines by elderberry supplements [46], el-
derberry supplements also have various kinds of other effects. Surely,
however, we should also weigh the benefit and risk for the use of el-
derberry supplements like other OTCs. We know that even OTCs (eg.
Tylenol) have many adverse effects on the drug information. In addi-
tion, we should also look at the Evidence-Based Systematic Review of
Elderberry and Elderflower (Sambucus nigra) by the Natural Standard
Research Collaboration [47], which could be applied to the current
COVID-19 pandemic.
In this point, we should be able to guide the use of these elderberry
supplements to the general population or patients with COVID-19 as
this: “Elderberry supplements can be used in those with COVID-19 at an
early course of disease, if you understand the previous efficacy of these
and potential adverse effects”.
6.4. The use of oral steroids at an early course of disease
Fourth, the use of oral steroids should be actively considered at an
early course of the disease. If the cause of death of COVID-19 is ARDS
and organ failure due to “cytokine storm” by hyperactivated host im-
mune response, why we are not considering to suppress or prevent this
process at an early course of the disease? We think the increase in
various pro-inflammatory cytokines induced by COVID-19 may be
suppressed by short-course low dose steroids in an early stage of dis-
ease, but it may not be effective in a later stage of disease such as ARDS
and multiorgan failure. This situation can be assimilated by forest fire.
If a first small fire by cigarette butts can be detected by hiker early
(early COVID-19), it can be extinguished by small amounts of water
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(low dose steroids) easily. But if wild forest fires spread (persistent high
fever, dyspnea) in the mountain without early suppression, it cannot be
suppressed despite every effort by numerous fire trucks (long-term use
of very high dose of steroids), and all mountains will be burned (des-
tructed lung, requiring ECMO). There was one recent systematic review
reporting that the use of steroids may be harmful to patients with
COVID-19 [48]. However, this result should be interpreted with caution
because the quality of the included studies is extremely low and they
have many biases, many studies are missing and the included studies
are not on the use of steroids vs. no use. This result should not be
generalized to the patients with early course of the disease and mild
symptoms.
One study investigated the structural arrangement of N protein,
explaining the first steps of its interaction with nucleic acid at the initial
stages of virus structure assembly [49]. The nucleocapsid (N) protein of
COVID-19 has nearly 90% amino acid sequence identity with SARS-CoV
and the N protein antibodies of SARS-CoV may cross react with COVID-
19 but may not provide cross-immunity. In a similar fashion to SARS-
CoV, the N protein of COVID-19 may play an important role in sup-
pressing the RNA interference (RNAi) to overcome the host defense
[50]. In rat models, the N-protein of SARS-CoV had pathogenicity and
could induce obvious pulmonary inflammatory reaction and acute lung
injury, which were related to the increase and imbalance of pro-in-
flammatory and anti-inflammatory cytokines. [51]. In this study, glu-
cocorticoids could effectively alleviate the pulmonary inflammatory
reaction induced by N-protein of SARS-CoV, supporting the beneficial
role of steroids on the inflammatory reactions caused by N-protein of
the current COVID-19 [51].
According to the Chinese government's daily report, 13.2–21.3% of
patients with COVID-19 developed severe or fatal illness, and therefore,
the China's National Health Commission released the fifth trial version
of Diagnosis and Treatment Scheme for Pneumonitis with COVID-19,
and provided a systematic treatment strategy for severe cases and sys-
tematic corticosteroids treatment (methylprednisolone, <1–2mg per
kg body weight, for 3–5 days) was recommended to be an adjuvant
therapy [52]. Zou et al. recently showed that systematic corticosteroids
therapy in the first 3–5 days in severe patients could enhance oxygen
saturation (SaO2) and arterial oxygen tension (PaO2)/inspiratory
oxygen fraction (FiO2), but corticosteroids did not exert any interven-
tion on survival of NCP patients complicated with both ARDS and shock
or multiple organ injury [53]. Nevertheless, they concluded that cor-
ticosteroids in the phase of ARDS would effectively inhibit furious in-
flammatory storm and gain valuable time for controlling infection and
preventing secondary multiorgan damage and shock, which implies
that corticosteroids have synergistic biological effects when combined
with other intensivists' treatment against severe or fatal NCP patients.
[53]. However, as we mentioned above, we think the increase in var-
ious pro-inflammatory cytokines induced by COVID-19 may be sup-
pressed by short-course low dose steroids in an early stage of disease,
but it may not be effective in a later stage of disease such as ARDS and
multiorgan failure because a later stage may be a big fire, which cannot
be suppressed easily.
One another thing is a short course of low dose oral steroids is easily
prescribed in the treatment of urticaria, but why are we afraid of pre-
scribing the use of oral steroids in the acute COVID-19 setting even
though many patients progress to severe disease, in whom there will be
some patients with mild symptoms with severe radiologic findings. If
we can lower the percentage of progressing to “cytokine storm” by early
use of steroids, even though it is found to be statistically nonsignificant,
such as p-value of 0.06–0.09, several patients will be rescued.
Therefore, we should interpret the results based on the p-value cau-
tiously and conversely, misinterpretation or misunderstanding of p-
value will cause a significant harm to the patients with COVID-19.
Recently, some groups showed the beneficial effect of hydroxy-
chloroquine [12]. Until these reports, there was evidence of hydroxy-
chloroquine on coronavirus just from in vitro study [54,55]. Therefore,
the doctor who first used this drug in a patient with COVID-19 might
have done this treatment by non-evidence-based medicine. We should
try the oral steroids in patients with COVID-19 at an early course of
disease.
6.5. The use of oral antibiotics
Fifth, the use of oral antibiotics should be actively considered if the
patient feels not good, because secondary bacterial infection might
aggravate acute immunological lung injury induced by several cyto-
kines (eg. IL-2, IL-6 and TNF-α) in COVID-19. There are no controlled
clinical trials evaluating the use of empiric antimicrobials in COVID-19
patients or other coronavirus driven diseases. Therefore, re-
commendations can only be based on other viral diseases like influenza
[56]. Furthermore, another guideline on treating COVID-19 patients
was released. Both guidelines suggest that blind or inappropriate use of
antibacterial drugs, especially the combination of broad-spectrum an-
tibacterial drugs should be avoided in patients with mild or no symp-
toms [57]. However, we are against these guidelines, because the cur-
rent COVID-19 situation is definitely different to other usual viral
infections, because some patients with mild symptoms can have severe
radiologic features and sudden death. Furthermore, bacterial super-
infection is hard to detect and cannot be easily diagnosed. Symptoms of
COVID-19 and bacterial superinfection may overlap. Data on the pre-
valence of bacterial superinfection in patients with COVID-19 are very
limited [58]. Influenza pneumonia is often associated with Staphylo-
coccus aureus co-infection and can be especially virulent [56]. Initiating
empiric antibacterial therapy in adults with community-acquired
pneumonia who test positive for influenza was recommended by recent
clinical practice guidelines [56]. Therefore, we suggest that according
to the clinical manifestations of patients, if the accompanying bacterial
infection cannot be ruled out, patients can take antibacterial drugs
against community-acquired pneumonia, such as amoxicillin, azi-
thromycin, or fluoroquinolones [57]. Empirical antibacterial treatment
in severe patients should cover all possible pathogens, deescalating
therapy until the pathogenic bacteria are clarified [59].
In addition, the current special situation should also be considered.
Currently, if the patient is diagnosed as having COVID-19, he/she will
be isolated at home and is recommended that if severe symptoms are
developed, come to the hospital and no medications are provided.
However, we think this is a very dangerous situation, because some
persons might have no or only mild symptoms despite severe progres-
sion of lung injury. And when these patients become to feel dyspnea,
and come to the hospital, the time might be late for the recovery. They
will receive not only intravenous antibiotics but also various kinds of
multiple drugs. We speculate that many patients who became to get
severe symptoms might have bacterial complications. It has been re-
ported that bacterial coinfection is associated with approximately 40%
of viral respiratory tract infections requiring hospitalization [60]. The
incidence of bacterial complications of COVID-19 is unknown yet, but
considering that more patients with COVID-19 get severe symptoms
than observed in other respiratory viral diseases, we speculate that
more bacterial complications might be combined not only in severe
conditions but also in mild conditions. If the patient is having usual
other respiratory viral infections, he/she will visit the clinic and will be
prescribed antibiotics. However, in the current situation, the patient
with COVID-19 cannot visit an usual clinic and should wait until he will
recover or get dyspnea. If virus damages the throat or lungs, other
bacteria oral cavity can cause secondary infection and this cannot be
exactly evaluated and diagnosed, because the laboratory examinations
for bacteria such as culture or procalcitonin may not be exact due to
false negative and all the bacteria cannot be examined.
In this situation, based on the medical principle “Do no harm”,
waiting until the patient deteriorate is a severe harm. Therefore, to
prevent the deterioration of the patient with COVID-19, oral antibiotics
and oral steroids should be given to the patient at the time of COVID-19
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and it should be recommended if the patient has high fever and feels
bad, take the antibiotics and steroids empirically and it can be accep-
table in the pandemic era as many patients are dying due to compli-
cations of COVID-19. If the doctor can monitor and guide the patients
with phone calls, it will be better if there are enough medical person-
nels, So, in the current situation, liberal and early use of oral antibiotics
and steroids may be “Do no harm”, which may be a different situation
than during the usual common cold situation. In our experiences, if the
patient feels bad, earlier antibiotics and steroids are used, the patient's
condition will recover.
6.6. The use of hydroxychloroquine
Sixth, hydroxychloroquine can be used as a secondary drug in pa-
tients with worsening symptoms in COVID-19. Chloroquine and its
metabolite, hydroxychloroquine, are antimalarial agents that have de-
monstrated antiviral effects on SARS-CoV and SARS-CoV-2 in vitro
[54,55]. Chloroquine had inhibitory effects for multiple RNA viruses in
vitro. Chloroquine showed no antiviral or clinical beneficial effects in
treatment of dengue and chikungunya virus infections and as influenza
prophylaxis [61]. A news briefing suggested that its use in more than
100 patients showed “that it was superior to the control in inhibiting
the exacerbation of pneumonia, improving lung imaging findings,
promoting a virus negative conversion, and shortening the disease
course”, but the data have not been published yet [62]. A recent con-
sensus document recommended chloroquine phosphate 500 mg twice
daily for minimum of 5 days [63]. Another study found hydroxy-
chloroquine more potent than chloroquine in vitro. Based on these data,
hydroxychloroquine for 4 days, 400 mg twice daily after a loading dose
of 400 mg was recommended [54]. A recent systematic review found no
published studies in COVID-19 patients [64]. Furthermore, adding
azithromycin to hydroxychloroquine 600 mg daily treatment seemed to
have a beneficial outcome in a small French cohort [12]. However, we
should also be cautious in interpreting the results of hydroxy-
chloroquine, because the current situation is just based on the in vitro
studies and small number of case series. Also, the adverse effects of
hydroxychloroquine should also be considered. In this situation, we
think hydroxychloroquine should not be used as a routine treatment of
COVID-19, but if the condition of the patients worsens despite the use of
steroids and antibiotics, hydroxychloroquine can be used as a secondary
drug.
6.7. Policy should be changed
Seventh, policy for the drug use should be changed to reduce the
mortality of patients. In usual situation, the patient can visit the clinic
frequently according to the condition. Therefore, steroids and anti-
biotics can be given timely based on the judgement of doctors.
However, this pattern of examination, diagnosis and treatment cannot
be done in this COVID-19 era. Doctors' prescriptions are surely im-
portant to diagnose and treat patients. However, as we mentioned
above, patients are just waiting for recovery or deterioration until se-
vere symptoms and no treatment is done in the meanwhile. If the pa-
tient is infected occur with COVID-19 and gets fever, and visit the
different clinics, the treatment will not be standardized among doctors.
If a doctor concerns for the fever and the nature of rapid deterioration
in COVID-19, he may use steroids and antibiotics early, while other
doctors may not. If so, we can make some guidelines for the practical
use of antibiotics, steroids and hydroxychloroquine for the patients to
use these drugs. These should also include the benefit and adverse effect
for each drug. The policy we are proposing is to give these drugs to the
patients freely, although the range of drug should also be more dis-
cussed. In Korea, the diagnosis of COVID-19 is being done by drive
through. Our suggestion is to make another drive through place to give
these drugs to the patients to avoid the dissemination of infection, be-
cause if the infected patient go to the hospital for the treatment, he/she
can infect all other patients. Also, it will be good if the drugs are given
to the patient who is visiting the screening clinic, for example, at the
time of drive through diagnosis and explain in detail the benefit and
adverse effect for each drug. And then, the doctor can check the result
for COVID-19 and guides the patient for taking the drugs by phone
calls. Also, the patient can take these drugs at his/her judgement. This
concept is based on that (1) any treatment for COVID-19 has not been
established, (2) even though the patient visits the doctor, the treatment
patterns will be all different among doctors, (3) steroids have frequently
been used in other mild diseases such as urticaria, (4) because we do
not exactly know the presence or absence of secondary infection when
the patient get fever, oral antibiotics for 3–4 days can be acceptable
treatment in routine clinical practice. Further, (5) hydroxychloroquine
can also be given to the patients and it can be recommended that if the
patient's symptoms worsen despite the use of steroids and antibiotics,
he/she can take hydroxychloroquine after recognizing all the adverse
effect of the drug. But if the symptoms worsen, the patient surely visit
the hospital as well.
7. Conclusions
COVID-19 is causing a severe public health emergency and the
mortality is rapidly increasing all over the word. In this era, we sug-
gested 7 recommendations to rescue the patients and to reduce the
morbidity and mortality due to COVID-19 based an immunological
point of view (Table 2). Ours may be personal opinions, but we believe
these may be beneficial to control these complications exerted by
COVID-19. In addition, there will be more other or conflicting evi-
dences and publications regarding our opinions. However, we would
like to remind of the basic principle for the treatment of patients again,
but we often forget this: “Do no harm”. We all should think deeply on
what is harm and what is no harm. In addition, we would like to say
again: “doing something is better than nothing.” in the acceptable level
of clinical practice. We hope that our opinions can be transferred to not
only WHO and CDC but also clinicians, researchers and many institu-
tions and COVID-19 could be finished as rapidly as possible.
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